TG THERAPEUTICS INC (TGTX:NASDAQ)
$36.28 -0.68 (-1.8398%)
Analysed TG THERAPEUTICS INC (TGTX:NASDAQ) News Sources
A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum
19-04-2026
yahoo.com
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi
16-04-2026
yahoo.com
TG Therapeutics concludes enrolment in Phase III Briumvi trial
16-04-2026
clinicaltrialsarena.com
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
15-04-2026
yahoo.com
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
03-04-2026
yahoo.com
A Look At TG Therapeutics (TGTX) Valuation After New US$750 Million Credit Facility
24-03-2026
yahoo.com
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
19-03-2026
yahoo.com
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment
16-03-2026
fool.com
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop
16-03-2026
fool.com
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX)
10-03-2026
yahoo.com
What is the current price of TG THERAPEUTICS INC (TGTX:NASDAQ)?
The current price of TG THERAPEUTICS INC (TGTX:NASDAQ) is $36.28.
TG THERAPEUTICS INC (TGTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of TG THERAPEUTICS INC (TGTX:NASDAQ) since the previous trading day is $-0.68.
TG THERAPEUTICS INC (TGTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of TG THERAPEUTICS INC (TGTX:NASDAQ) since the previous trading day is -1.8398%.
What is the most recent average sentiment score for TG THERAPEUTICS INC (TGTX:NASDAQ)?
The most recent average sentiment score for TG THERAPEUTICS INC (TGTX:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for TG THERAPEUTICS INC (TGTX:NASDAQ)?
The most recent sentiment for TG THERAPEUTICS INC (TGTX:NASDAQ) is .
SEC-8K** Filing Available For TG THERAPEUTICS INC (TGTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.